- Home
- » Tags
- » Dipropyltryptamine
Top View
- GOODFELLAS Index No.C'0;Z U'd
- New Psychoactive Substances (NPS)
- Β-Arrestin 1 and 2 Modulation of LSD-Evoked Responses
- New Psychoactive Substances in Australia
- Drugs on the Web; the Psychonaut 2002 EU Project
- Summary of 2020 Legislation
- Tihkal: the Continuation, by Alexander and Ann Shulgin
- The Psychedelic Religion of Mystical Consciousness
- Controlled Substances List (Adopted by Alabama State Board of Health on January 20, 2021, Effective January 20, 2021)
- Improved Forensic Toxicology Screening Using a GC/MS/NPD System with a 725-Compound DRS Database
- Optimization of Separation and Online Sample Concentration of N,N
- 054 Tryptamine Trauma! N,N-Dipropyltryptamine Associated
- WO 2010/151258 Al
- Statistical and Mass Spectral Tools for the Identification and Characterization of Synthetic Phenethylamines Author(S): Ruth Waddell Smith, A
- In Vitro Screening of Psychoactive Drugs by [35S] Gtpγs Binding In
- The Role of Psychedelics in Medicine: Historical Context and Current Clinical Applications
- Studying the Effects of Classic Hallucinogens in the Treatment of Alcoholism: Rationale, Methodology, and Current Research with Psilocybin Michael P
- List of Scheduling Actions, Controlled Substances And
- Psychoactive N,N-Dialkyltryptamines Modulate Serotonin Transport by at Least Two Mechanisms
- Comparison of the Behavioral Effects of Mescaline Analogs Using The
- The Distortion of Music by Dr
- Substance Abuse in the Workplaces of Our Bodies and Mind
- Hallucinogens
- 2014 SENATOR AMENDMENT Bill No. CS for CS for SB 1030
- NIDA - Director's Report - May, 2011
- Neuropharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”) and Its Stereoisomers
- The Role of Psychedelics in Palliative Care Reconsidered: a Case for Psilocybin
- Laboratory Licensure As of July 2003
- View Library
- The Hallucinogenic World of Tryptamines: an Updated Review
- Receptor Binding Profiles and Behavioral Pharmacology of Ring
- Therapeutic Mechanisms of Classic Hallucinogens in the Treatment of Addictions: from Indirect Evidence to Testable Hypotheses Michael P
- Joseph H. Porter · Adam J. Prus Editors the Behavioral Neuroscience of Drug Discrimination Current Topics in Behavioral Neurosciences
- Drugs of Abuse, a DEA Resource Guide (2020 Edition)
- Download Product Insert (PDF)
- Toronto Forensic
- Tryptamine Derivatives
- Toxicology and Analysis of Psychoactive Tryptamines
- 159 2004 & 2005 Index
- Newer Unregulated Drugs
- New MDMA Research at the 65Th Annual Meeting of the College on Problems of Drug Dependence (CPDD) – June 14-19, 2003, Sheraton Bal Harbour, Miami, Florida
- Designer Drugs: Mechanism of Action and Adverse Effects
- Do Hallucinogens Cause Residual Neuropsychological Toxicity?
- Toxicology Reference Material
- Quantitative Analysis of Narrative Reports of Psychedelic Drugs
- The Dynamic Field of Psychedelic Research: Trials and Projects